CD19 CAR T cells for B cell malignancies: a systematic review and meta-analysis focused on clinical impacts of CAR structural domains, manufacturing conditions, cellular product, doses, patient’s age, and tumor types
Abstract CD19-targeted chimeric antigen receptors (CAR) T cells are one of the most remarkable cellular therapies for managing B cell malignancies. However, long-term disease-free survival is still a challenge to overcome. Here, we evaluated the influence of different hinge, transmembrane (TM), and...
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
BMC
2024-08-01
|
| Colección: | BMC Cancer |
| Materias: | |
| Acceso en línea: | https://doi.org/10.1186/s12885-024-12651-6 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|